RecruitingEarly Phase 1NCT07680257

An Early Clinical Study to Evaluate the Safety and Efficacy of CLDN18.2 CAR T Cell Injection in Subjects With CLDN18.2-Positive Advanced Malignant Solid Tumors

Sponsor

Celest Therapeutics (Shanghai) Co., Ltd.

Enrollment

18 participants

Start Date

Dec 27, 2025

Study Type

INTERVENTIONAL

Conditions

CLDN18.2 Positive Solid Tumors

Summary

An open label, single/multiple dose exploratory clinical study to evaluate the safety, efficacy, and pharmacokinetics of autologous humanized anti-claudin18.2 chimeric antigen receptor T cell in advanced solid tumor.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called SUV2208A, a biological treatment called SUV2208A, and others for people with cldn18.2 positive solid tumors. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALSUV2208A cell injection

SUV2208A, DL1, 2 times, Day 0 and Day 28, IV

BIOLOGICALSUV2208A

SUV2208A, DL2, 2 times, Day 0 and Day 28, IV

BIOLOGICALSUV2208A

SUV2208A, DL3, 2 times, Day 0 and Day 28, IV

Locations(1)

The First Affiliated Hospital Of Anhui Medical University

Hefei, Anhui, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07680257